Heart Failure

The AJMC^® Heart Failure compendium is a comprehensive resource for clinical news and expert insights for the chronic condition in which the heart doesn't pump enough blood due to damaged heart muscle.

Latest News

AJMC

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

By Mario Enrico Canonico, MD, PhD
Judith Hsia, MD

August 14th 2025

The analysis highlighted a shift in heart failure diagnoses, with hypertensive heart disease with and without chronic kidney disease as prevalent diagnoses, underlining coding variability and implications for research.

A new clinical drug trial tests the efficacy and safety of finerenone, used to help reduce potassium expulsion for people on diuretics. | Image Credit: AdobeStock_ PhotobyTawat.jpeg

Finerenone Demonstrates Safety and Efficacy in Heart Failure When Combined With Diuretics

By Sabrina McCrear

August 13th 2025

Genetic factors may increase the risk of developing dilated cardiomyopathy in addition to covariates like age and sex. | Image Credit: AdobeStock_jaojormami.jpeg

Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation

By Sabrina McCrear

August 13th 2025

Left bundle branch block may be an significant indicator of heart failure succeeding previous risk-factors like diabetes and hypertension. | Image Credit: AdobeStock_phonlamaiphoto.jpeg

Left Bundle Branch Block May Be Key Indicator of Progressive Heart Failure

By Sabrina McCrear

August 8th 2025

Researchers measured physical activity trajectories before and after CVD events like coronary heart disease, stroke, and heart failure. | Image Credit: LIGHTFIELDSTUDIOS - stock.adobe.com

Strategies Needed to Address Physical Activity Before, After CVD Events

By Sabrina McCrear

August 1st 2025

Continuing Medical Education

August 21st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 21st 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

August 21st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

August 21st 2025

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

1.5 Credits / Cardiology

August 21st 2025

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

1.5 Credits / Cardiology, Rare Diseases

August 21st 2025

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

1.5 Credits / Pulmonology, Cardiology, Rare Diseases

More News

Mortality, Risk Factors of Patients With Cardiac Injury and COVID-19

March 25th 2020

Mortality, Risk Factors of Patients With Cardiac Injury and COVID-19

Evidence is considered lacking on the association between mortality and patients who have both cardiac injury and coronavirus disease 2019 (COVID-19). Is the rate of death higher among these patients compared with patients without cardiac disease who have COVID-19?

Clinical Variable Model More Reliable at Predicting Mortality Among Veterans

March 22nd 2020

Clinical Variable Model More Reliable at Predicting Mortality Among Veterans

Are coding changes responsible for declines in the 30-day mortality rate for hospital admissions among veterans utilizing Veterans Health Administration medical centers? Which model is more accurate at predicting this measure: a claims-based model or a clinical factor–based model?

Palliative Care Is Underutilized for Patients With Heart Failure

March 20th 2020

Palliative Care Is Underutilized for Patients With Heart Failure

By 2030, heart failure—which tops the list of reasons for hospitalization among individuals older than 65 years—could tax the healthcare system $69.8 billion each year. Study results show the success of palliative care at reducing both healthcare costs and hospitalization.

How Vulnerable Are Patients With Cardiovascular Disease to COVID-19, Flu Complications?

March 12th 2020

How Vulnerable Are Patients With Cardiovascular Disease to COVID-19, Flu Complications?

Patients with cardiovascular disease are especially vulnerable to respiratory infections, although uncertainty remains on just what damage COVID-19 can cause in these patients. The flu season is also in full swing, with an estimated 440,000 individuals hospitalized so far in the United States alone, according to the CDC.

Wearable Sensor May Help Reduce Subsequent Heart Failure Hospitalization, Costs

March 4th 2020

Wearable Sensor May Help Reduce Subsequent Heart Failure Hospitalization, Costs

Eighty percent of annual costs for heart failure come from hospitalization for the condition, which more than 23 million persons suffer from worldwide, 6.2 million (27%) in the United States alone. These costs are estimated to increase almost 58% between 2012 and 2030, from $30.7 billion to $53 billion.

Bringing a Precision Medicine Approach to Heart Failure

February 29th 2020

Bringing a Precision Medicine Approach to Heart Failure

Barriers to better treatment start with the basic definitions of heart failure. Classifications in use for decades, such as the New York Heart Association system or the left ventricle ejection fraction measure, need an overhaul, and the field should take a precision medicine approach that brings analytics and biomarkers to the cause.

Canagliflozin Conveys Lower Risk of Adverse CV Events in Patients With High CV Risk, T2D

February 27th 2020

Canagliflozin Conveys Lower Risk of Adverse CV Events in Patients With High CV Risk, T2D

Updated results from the EASEL study show that lower risks of cardiovascular (CV) events, CV death, and CV mortality accompany initiation of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes (T2D) and high CV risk compared with use of other drugs.

Sudden Cardiac Death, Heart Disease Surprise More Women Than Men

February 21st 2020

Sudden Cardiac Death, Heart Disease Surprise More Women Than Men

Circulation, a peer-reviewed journal of the American Heart Association, just released its fourth annual Go Red for Women issue, in which researchers from the Smidt Heart Institute at Cedars-Sinai note the stark disparities in how heart disease manifests in women and men. For women, sudden cardiac death is often the first sign they even have heart disease.

What Other Condition Might Dapagliflozin Prevent? How About Afib?

February 14th 2020

What Other Condition Might Dapagliflozin Prevent? How About Afib?

Competing trials are under way that may show that the benefits of SGLT2 inhibitors in heart failure are a class effect.

Heart Disease and Smoking Are Locked in an Ongoing Battle Against Patient Health

February 11th 2020

Heart Disease and Smoking Are Locked in an Ongoing Battle Against Patient Health

There are more than 36 million smokers in the United States today, and most (70%) admit they want to quit. Individuals who decide to quit see a smaller risk of heart disease within 1 to 2 years, along with reduced risks of stroke and peripheral vascular disease. However, annual deaths from smoking still exceed 480,000 in the United States, where over 16 million live with smoking-related diseases that include infertility, lung cancer, and chronic obstructive pulmonary disease.

Dr Roland Chen: BMS, Pfizer Committed to Improving Care for Patients With Atrial Fibrillation

February 10th 2020

Dr Roland Chen: BMS, Pfizer Committed to Improving Care for Patients With Atrial Fibrillation

GUARD-AF is an example of the commitment of the BMS, Pfizer Alliance in trying to further the standard of care in patients with atrial fibrillation, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.

Are Prognostic Models Accurate at Predicting Mortality, Morbidity in Patients With Chronic Heart Failure?

February 8th 2020

Are Prognostic Models Accurate at Predicting Mortality, Morbidity in Patients With Chronic Heart Failure?

In 2017, heart failure contributed to 1 in 8 deaths. This inability of the heart to function at its optimal level led to an estimated $30.7 billion in annual healthcare costs in 2012, including healthcare services, medicines, and missed work.

Deeper Dive Into Rosiglitazone Data Reveals Link to CV Risk, Especially Heart Failure

February 6th 2020

Deeper Dive Into Rosiglitazone Data Reveals Link to CV Risk, Especially Heart Failure

The most detailed look ever at data for rosiglitazone, the diabetes drug marketed by GlaxoSmithKline (GSK) as Avandia, shows the one-time blockbuster significantly raises the overall risk of heart problems or cardiovascular death, calling attention to the need for more transparency in data collection.

Dr Javed Butler: Recognizing Risk of Heart Failure in Patients With Diabetes Key to Preventive Care

February 1st 2020

Dr Javed Butler: Recognizing Risk of Heart Failure in Patients With Diabetes Key to Preventive Care

Improving recognition of the link between heart failure and diabetes can promote preventive care for at-risk patients, said Javed Butler, MD, MPH, MBA, professor of physiology and chairman for the Department of Medicine at the University of Mississippi.

Shock Only or Drug-Shock? 2 Different Cardioversion Techniques Equally Effective, Study Says

January 31st 2020

Shock Only or Drug-Shock? 2 Different Cardioversion Techniques Equally Effective, Study Says

Allison Inserro

The drug-shock strategy was more effective for patients experiencing atrial fibrillation for the first time and for patients younger than 70 years, the researchers said.

Are Transitional Care Services Worth Investing In for Heart Failure?

January 28th 2020

Are Transitional Care Services Worth Investing In for Heart Failure?

Heart failure (HF) taxes the American healthcare system by a total of $39.2 billion to $60 billion each year. This amount is expected to increase up to 20% by 2030 and total $70 billion. Worldwide, HF has been diagnosed in 26 million individuals, and this number is rising.

Experiments Give Insights Into Dapagliflozin's Cardioprotective Effects

January 25th 2020

Experiments Give Insights Into Dapagliflozin's Cardioprotective Effects

The authors write that the drug's apparent cardioprotective effects in the angiotensin II stressed mice—the decreased fibrosis, reduced inflammation and oxidative stress—all merit further study.

Does Excess Body Weight Equal Adverse Heart Health Outcomes?

January 20th 2020

Does Excess Body Weight Equal Adverse Heart Health Outcomes?

Hypertrophic cardiomyopathy is an abnormal thickening of the heart muscle, with causes that include genetic mutations and myofiber disarray (an abnormal heart muscle cell arrangement). Individuals who have this condition are prone to obesity (body mass index, 25 to

Dr Javed Butler on Importance of Diabetes Can Break Your Heart Initiative for American Heart Month

January 19th 2020

Dr Javed Butler on Importance of Diabetes Can Break Your Heart Initiative for American Heart Month

Diabetes Can Break Your Heart is an important initiative that highlights the vital need for heightened education on the link between diabetes and heart failure, especially with American Heart Month looming, said Javed Butler, MD, MPH, MBA, professor of physiology and chairman for the Department of Medicine at the University of Mississippi.

What We're Reading: Improvements in Health Disparities Stall; Reanimating Hearts; Aging Population Concerns

January 16th 2020

What We're Reading: Improvements in Health Disparities Stall; Reanimating Hearts; Aging Population Concerns

Since 2016, racial and ethnic healthcare disparities have not improved; a new method of "reanimating" hearts from recently deceased donors for transplants is being tested; the new decade prompts concerns about an aging population.

Risk of Heart Disease Among Childhood Cancer Survivors Falls Since 1970s, Data Show

January 16th 2020

Risk of Heart Disease Among Childhood Cancer Survivors Falls Since 1970s, Data Show

While the number of survivors who had cardiotoxic treatments increased, the doses they received decreased. Radiation exposure fell from 77% in the 1970s to 40% in the 1990s.

Suggested Link Between Regional Heart Failure Treatment Gaps, Patient Outcomes

January 15th 2020

Suggested Link Between Regional Heart Failure Treatment Gaps, Patient Outcomes

The median time to first intravenous therapy for acute heart failure (AHF) is 3.0 hours in North America compared with 1.2 hours in all other regions, in the International Registry to Assess Medical Practice with Longitudinal Observation for Treatment of Heart Failure. Treatment timing and differences may affect outcomes in patients with AHF.

Dr Javed Butler Discusses Why People With Diabetes Are at Greater Risk of Heart Failure

January 11th 2020

Dr Javed Butler Discusses Why People With Diabetes Are at Greater Risk of Heart Failure

There are multiple ways in which people with diabetes can develop heart failure, which is why heightened awareness through the initiative Diabetes Can Break Your Heart is warranted, said Javed Butler, MD, MPH, MBA, professor of physiology and chairman for the Department of Medicine at the University of Mississippi.

Patients Hospitalized for Heart Failure Have 11 Times the Risk of Kidney Failure

January 10th 2020

Patients Hospitalized for Heart Failure Have 11 Times the Risk of Kidney Failure

Hospitalizations due to heart failure (HF) were associated with a risk for kidney failure (KF) that was 11.4-times greater compared with patients who did not have cardiovascular disease (CVD). Among a group of CVDs that also included atrial fibrillation, coronary heart disease, and stroke, HF was associated with the highest risk of developing subsequent KF.

FDA Grants Dapagliflozin Priority Review for Heart Failure, Even for Those Without Diabetes

January 9th 2020

FDA Grants Dapagliflozin Priority Review for Heart Failure, Even for Those Without Diabetes

Priority review was based on phase 3 results from DAPA-HF, presented in Paris at the European Society of Cardiology and published in the New England Journal of Medicine.

Timing, Accessibility of Resources Key to Effective Treatment of Fulminant Myocarditis

January 7th 2020

Timing, Accessibility of Resources Key to Effective Treatment of Fulminant Myocarditis

Matthew Gavidia

In a statement published today by he American Heart Association, researchers provide key resources needed to diagnose and treat fulminant myocarditis successfully.

The Great Revascularization Strategy Debate: Coronary Artery Bypass Graft or Percutaneous Coronary Intervention?

December 30th 2019

The Great Revascularization Strategy Debate: Coronary Artery Bypass Graft or Percutaneous Coronary Intervention?

Patients with acute heart failure often require immediate treatment to restore optimal heart function. The 2 primary methods of revascularization are coronary artery bypass graft and percutaneous coronary intervention, but the preferred strategy for use in these patients requires clarification due to risk.

Socioeconomic Status Tied to Risk of Chronic Disease, Including Cardiac, Diabetes

December 21st 2019

Socioeconomic Status Tied to Risk of Chronic Disease, Including Cardiac, Diabetes

Sara Karlovitch

Social inequalities are created before the onset of the illness, rather than after it, according to researchers.

Healthcare, Genetic Testing Disparities Persist in Black Patients With Hypertrophic Cardiomyopathy

December 19th 2019

Healthcare, Genetic Testing Disparities Persist in Black Patients With Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is an inherited condition in which mutations in genes that encode the sarcomere proteins in the heart cause an abnormal thickening of that muscle, with no known cure. In black patients, HCM is usually diagnosed at a younger age and accompanied by a greater burden of symptomatic heart failure. These patients, however, are not well represented in surveys of the condition, which tend to focus on white patients.

Is There a Future for CAR T-Cell Therapy in Heart Failure?

December 13th 2019

Is There a Future for CAR T-Cell Therapy in Heart Failure?

Chimeric antigen receptor (CAR) T cells are lymphocytes genetically engineered to recognize and bind to specific proteins on cancer cells. Studies are currently underway for applications in other fields.

...

11 12 13 14 15 16 17 18 19

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions